Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) Given Average Recommendation of “Buy” by Brokerages

Hikma Pharmaceuticals PLC (OTCMKTS:HKMPFGet Rating) has been assigned an average rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $1,465.50.

HKMPF has been the subject of a number of recent research reports. Peel Hunt raised shares of Hikma Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, January 20th. Zacks Investment Research raised shares of Hikma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research note on Wednesday. JPMorgan Chase & Co. reduced their price objective on shares of Hikma Pharmaceuticals from GBX 3,000 ($38.24) to GBX 2,900 ($36.96) in a research note on Wednesday, March 2nd. Finally, Morgan Stanley lowered shares of Hikma Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a report on Thursday, March 3rd.

Hikma Pharmaceuticals stock opened at $28.00 on Friday. The company has a 50 day moving average price of $26.83 and a 200-day moving average price of $28.60. The company has a quick ratio of 1.38, a current ratio of 2.06 and a debt-to-equity ratio of 0.29. Hikma Pharmaceuticals has a fifty-two week low of $24.30 and a fifty-two week high of $37.70.

Hikma Pharmaceuticals Company Profile (Get Rating)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

Recommended Stories

Analyst Recommendations for Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.